Risk Factors for Chronic Damage Accumulation Across Different Onset Eras in Systemic Lupus Erythematosus: A Cross-sectional Analysis of a Lupus Registry of Nationwide Institutions (LUNA)
| Autor: | Ohashi, K., Sada, K. -E, Asano, Y., Hayashi, K., Yamamura, Y., Asano, S. H., Miyawaki, Y., Morishita, M., Katsuyama, E., Watanabe, H., Tatebe, N., Narazaki, M., Matsumoto, Y., Sunahori-Watanabe, K., Kawabata, T., Yajima, N., Jun Wada |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Adolescent glucocorticoids disease activity Middle Aged Young Adult Cross-Sectional Studies systemic lupus erythematosus chronic damage Risk Factors Disease Progression Quality of Life Humans Lupus Erythematosus Systemic Female Registries disease duration Age of Onset Glucocorticoids Immunosuppressive Agents |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0386-300X |
| Popis: | Chronic damage accumulation affects not only mortality but also quality of life in patients with systemic lupus erythematosus (SLE). Risk factors for chronic damage were explored in SLE through different onset eras. Two hundred forty-five patients at Okayama University Hospital and Showa University Hospital were divided into three groups based on the onset era: a past-onset group (onset before 1995; n=83), middle-onset group (1996-2009; n=88), and recent-onset group (after 2010; n=74). The mean Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score as an index of chronic damage was 1.93, 1.24, and 0.53 in the past-, middle-, and recent-onset groups, respectively. In the pastonset group, the total SDI score was significantly associated with glucocorticoid monotherapy by linear regression analysis (β-coefficient [β]=0.63; 95% confidence interval [CI], 0.21-1.05) and C-reactive protein levels (β=0.67; 95% CI, 0.27-1.07). In the middle-onset group, the total SDI score was significantly associated with the SLE Disease Activity Index at registration (β=0.09; 95% CI, 0.03-0.12). Reducing the accumulation of chronic damage in SLE patients might be possible with the concomitant use of immunosuppressants and tight control of disease activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|